Evotec (NASDAQ:EVO) Lowered to Hold at Deutsche Bank Aktiengesellschaft

Evotec (NASDAQ:EVO) was downgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Marketbeat Ratings reports.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Evotec in a research report on Thursday, May 23rd.

Evotec Trading Down 2.6 %

Shares of NASDAQ:EVO opened at $4.94 on Thursday. The business has a fifty day moving average price of $4.91 and a two-hundred day moving average price of $6.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.79 and a current ratio of 1.86. Evotec has a 1 year low of $3.94 and a 1 year high of $13.49.

Institutional Investors Weigh In On Evotec

Several institutional investors have recently added to or reduced their stakes in EVO. Mubadala Investment Co PJSC bought a new position in shares of Evotec in the fourth quarter worth $53,931,000. Optiver Holding B.V. lifted its holdings in Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares in the last quarter. Cetera Advisors LLC bought a new position in Evotec in the 1st quarter worth about $188,000. Finally, Quadrant Capital Group LLC purchased a new position in Evotec during the 4th quarter valued at about $25,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.